Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 303.47M | 228.26M | 217.77M | 187.51M | 190.19M | 175.69M |
Gross Profit | 268.17M | 214.71M | 208.18M | 178.13M | 186.62M | 170.98M |
EBITDA | 306.53M | 211.54M | 145.80M | 162.81M | 161.96M | 157.38M |
Net Income | 219.74M | 125.08M | 53.73M | 42.87M | 48.30M | 57.21M |
Balance Sheet | ||||||
Total Assets | 4.66B | 3.44B | 2.08B | 1.62B | 1.64B | 1.50B |
Cash, Cash Equivalents and Short-Term Investments | 306.05M | 213.82M | 294.45M | 13.18M | 19.89M | 18.92M |
Total Debt | 0.00 | 396.93M | 595.60M | 719.50M | 673.40M | 545.59M |
Total Liabilities | 1.33B | 507.63M | 666.12M | 771.41M | 725.09M | 589.42M |
Stockholders Equity | 3.30B | 2.91B | 1.42B | 849.37M | 915.76M | 914.14M |
Cash Flow | ||||||
Free Cash Flow | 301.10M | 236.20M | 143.79M | 137.12M | 150.86M | 137.44M |
Operating Cash Flow | 314.61M | 244.25M | 154.77M | 144.41M | 156.87M | 145.74M |
Investing Cash Flow | -1.87B | -1.51B | -267.81M | -127.40M | -192.63M | -41.58M |
Financing Cash Flow | 1.37B | 1.19B | 394.32M | -23.73M | 36.74M | -105.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $7.67B | 28.95 | 8.36% | 3.64% | 50.84% | 104.44% | |
79 Outperform | 3.73B | 25.30 | 10.10% | 4.59% | 6.87% | 7.23% | |
76 Outperform | 12.25B | 26.04 | 9.44% | 6.45% | 12.73% | 23.51% | |
74 Outperform | 4.49B | 24.81 | 6.72% | 6.41% | 6.89% | 240.70% | |
70 Neutral | 7.20B | -192.35 | -1.35% | 2.37% | 11.62% | 0.00% | |
60 Neutral | 6.36B | -15.68 | -8.38% | 6.47% | -7.16% | 23.40% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% |
On August 12, 2025, CareTrust REIT, Inc. entered into an underwriting agreement with major financial institutions to sell 20,000,000 shares of its common stock at $32.00 per share, with an option for an additional 3,000,000 shares, which was fully exercised the next day. The issuance of these shares, completed on August 14, 2025, was part of a strategic move to enhance the company’s financial positioning and potentially expand its operations within the healthcare real estate sector.
The most recent analyst rating on (CTRE) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on CareTrust REIT stock, see the CTRE Stock Forecast page.